First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
Sign Up to like & getrecommendations! Published in 2021 at "Signal Transduction and Targeted Therapy"
DOI: 10.1038/s41392-021-00813-y
Abstract: In the ARTEMIS-CTONG1509 multicenter phase 3 study recently published in Cancer Cell, Zhou et al. investigate the combination of the EGFR tyrosine kinase inhibitor (TKI) erlotinib and antiangiogenic bevacizumab in treatment-naive Chinese patients with advanced… read more here.
Keywords: egfr mutant; line anti; vegf plus; anti vegf ... See more keywords